KALA BIO, Inc. SEC filings KALA
KALA BIO, Inc. has 675 filings in SEC EDGAR's recent list, going back to Dec 23, 2009. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 19, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-Q | Filing | Aug 14, 2026 | Jun 30, 2026 |
| EFFECT | Filing | Jun 25, 2026 | — |
| NT 10-K | Filing | Mar 31, 2026 | Dec 31, 2025 |
| D | Filing | Mar 17, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 13, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 13, 2026 | — |
| D | Filing | Feb 13, 2026 | — |
| PRER14A | Filing | Dec 19, 2025 | — |
| NT 10-Q | Filing | Nov 14, 2025 | Sep 30, 2025 |
| EFFECT | Filing | Feb 4, 2025 | — |
| CORRESP | Letter to the SEC | Jan 31, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 31, 2025 | — |
| D | Filing | Dec 31, 2024 | — |
| EFFECT | Filing | Jul 31, 2024 | — |
| CORRESP | Letter to the SEC | Jul 29, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2024 | — |
| D | Filing | Jun 28, 2024 | — |
| SC TO-I/A | Filing | May 31, 2023 | — |
| EFFECT | Filing | May 11, 2023 | — |
| SC TO-I/A | Filing | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 9, 2023 | — |
| SC TO-I | Filing | May 1, 2023 | — |
| EFFECT | Filing | Mar 14, 2023 | — |
| CORRESP | Letter to the SEC | Mar 10, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2023 | — |
| 8-A12G | Filing | Aug 19, 2022 | — |
| D | Filing | Nov 29, 2021 | — |
| CT ORDER | Filing | Jul 15, 2021 | — |
| EFFECT | Filing | May 19, 2020 | — |
| CORRESP | Letter to the SEC | May 15, 2020 | — |
| UPLOAD | Letter from the SEC | May 13, 2020 | — |
| CT ORDER | Filing | May 1, 2020 | — |
| CT ORDER | Filing | Oct 9, 2018 | — |
| EFFECT | Filing | Aug 27, 2018 | — |
| CORRESP | Letter to the SEC | Aug 23, 2018 | — |
| CT ORDER | Filing | Aug 22, 2018 | — |
| CORRESP | Letter to the SEC | Aug 20, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2018 | — |
| CT ORDER | Filing | Apr 19, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2017 | — |
| CT ORDER | Filing | Jul 20, 2017 | — |
| EFFECT | Filing | Jul 19, 2017 | — |
| CORRESP | Letter to the SEC | Jul 17, 2017 | — |
| CORRESP | Letter to the SEC | Jul 17, 2017 | — |
| 8-A12B | Filing | Jul 14, 2017 | — |
| CORRESP | Letter to the SEC | Jun 28, 2017 | — |
| CORRESP | Letter to the SEC | Jun 23, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2017 | — |
| DRSLTR | Filing | Jun 2, 2017 | — |
| DRS/A | Filing | Jun 2, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 26, 2017 | — |
| DRS/A | Filing | Mar 30, 2017 | — |
| D | Filing | Apr 13, 2016 | — |
| DRS/A | Filing | Feb 4, 2016 | — |
| DRSLTR | Filing | Nov 3, 2015 | — |
| DRS/A | Filing | Nov 3, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 20, 2015 | — |
| DRS | Filing | Sep 21, 2015 | — |
| D | Filing | Aug 19, 2015 | — |
| D | Filing | Apr 24, 2014 | — |
| D | Filing | Feb 28, 2013 | — |
| D | Filing | Mar 14, 2012 | — |
| D | Filing | Nov 10, 2010 | — |
| D | Filing | Dec 23, 2009 | — |
Showing 66 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KALA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479419
- Former names
- KALA BIO, Inc. (until Nov 3, 2026); Kala Pharmaceuticals, Inc. (until Jun 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.